On August 28, 2024, Eli Lilly and Company submitted a nomination to request that its GLP-1 product, tirzepatide, be added to FDAs Demonstrable Difficulties for Compounding (DDC) lists
Because of this triple-action mechanism, researchers often call it a GLP-3 peptide
doi:10.1016/j.brainres.2005.03.031
This is typically a longer-term treatment commitment
Retinal complications called diabetic retinopathy worsening have appeared in trial data, primarily in patients with existing diabetes
When blood glucose drops too low, fatigue, weakness, and confusion are characteristic symptoms